Bioasis Technologies (TSX.V:BTI; OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of central nervous system (CNS) disorders, today announced the close of...
Tailwinds' Take: This is excellent progress. If it translates into human data, a decent probability, it could be huge. Once they get properly funded and on Nasdaq, Bioasis should start to attract some real investor attention. We entered early...
RICHMOND, British Columbia & GUILFORD, Conn. & DURHAM, N.C.–(Business Wire)– Bioasis Technologies, Inc . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, and BIOAGILYTIX ,...
Tailwinds' Take: Scientists of this caliber don't join SABs unless there's something exciting going on. We eagerly anticipate the release of Non-Human Primate data sometime (hopefully) soon. RICHMOND, British Columbia &  GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company...
The Big Picture Sometimes you get a little out of touch living in California (duh!). For one thing, the lack of a real winter can really obfuscate the fact that summer is coming. However, as I currently sit on a...
Tailwinds' Take: Great news! xB3 is poised to be a game-changing platform for treatment of CNS diseases. Still early stage, but the opportunity deserves a higher valuation. When they list in the US (later this year?), Bioasis stock could...
Tailwinds' Take: having a manufacturing partner is a key step towards clinical development of their drug candidates. With their recent financing, which we believe had large insider participation, behind them, we would expect to see more press releases out...
Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not only reveal their sales and profits, but, typically, they provide guidance (either specifically or in...
Tailwinds' Take: the closing of this private placement is a key catalyst for Bioasis shares. We have been adding in the Tailwinds portfolios and look forward to seeing how details concerning the level of insider participation. If insiders were...
When I removed Bioasis from the Tailwinds Select Portfolio, it was with great reluctance. This is a Company that I believe has groundbreaking, lifesaving, technology. The management team is strong and the board is outstanding. All the pieces were...